Clinical trials often involve several external organizations, and the roles of those organizations can overlap in ways that are not immediately obvious. Two commonly encountered models are contract research organizations (CROs) and site management organizations (SMOs). Although both can support clinical trials, they generally operate at different points in the trial ecosystem.
A CRO may take responsibility for activities delegated by the sponsor across areas such as clinical operations, monitoring, data management, regulatory work, or other trial functions. An SMO, by contrast, focuses more directly on operational support at clinical research sites, often working with investigators and site staff. Understanding this distinction is useful when a sponsor uses both providers within the same study.
What Is the Difference Between a CRO and an SMO?
The main difference is the level at which the two organizations typically operate. A CRO can manage or coordinate broad trial activities on behalf of a sponsor, while an SMO primarily supports the day-to-day operational needs of participating research sites.
FDA regulations define a CRO as an independent organization contracted by a sponsor to assume one or more obligations related to the conduct of a clinical investigation. The activities transferred to a CRO should be clearly documented, while the sponsor retains overall responsibility for its applicable trial activities and appropriate oversight of transferred activities.
An SMO is more closely connected to the investigator site. Its personnel may support activities such as site coordination, study documentation, study visit coordination, and communication between the site and other study stakeholders. The precise scope varies according to the service agreement and local operating model.
This distinction does not mean that an SMO replaces a CRO. In a multi-provider study, the two can perform complementary functions.
What Does an SMO Do at the Clinical Trial Site?
An SMO primarily provides operational support that helps research sites conduct their assigned trial activities. The work is often performed through clinical research coordinators (CRCs) or other trained site-support personnel.
At the site level, responsibilities can include coordinating study visits, maintaining trial documentation, supporting communication with investigators, tracking study activities, and assisting with processes associated with recruitment and enrollment. The exact duties depend on the activities assigned under the applicable agreements and delegation arrangements, as well as local regulatory requirements.
FDA guidance has specifically discussed situations in which an SMO employs study coordinators or other staff supporting an investigator. In such cases, the investigator remains responsible for supervising delegated study tasks and ensuring that personnel are appropriately qualified and trained.
This makes the SMO’s position distinctive: it provides operational resources at the site while working within the investigator’s clinical and regulatory responsibilities.
What Does a CRO Typically Manage?
A CRO can operate at a broader study-management level. Depending on the sponsor’s agreement, its responsibilities may include clinical operations, monitoring, project management, data management, biostatistics, regulatory activities, medical writing, and other functions.
For example, a CRO may, as assigned by the sponsor, develop a monitoring approach, coordinate multiple study sites, manage study-level timelines, oversee data processes, and communicate overall trial progress to the sponsor. The scope is determined by the responsibilities formally transferred by the sponsor.
FDA guidance on risk-based monitoring notes that sponsors may delegate monitoring responsibilities to CROs, while retaining oversight of the work performed by those organizations.
The CRO therefore often serves as a study-level coordination layer, whereas the SMO is positioned closer to the operational realities of individual research sites.
When Would a Sponsor Use Both an SMO and a CRO?
Using both providers can make sense when a sponsor wants centralized trial management while also requiring dedicated operational support at participating sites.
For example, a CRO may manage the overall study, monitoring plan, data flow, and sponsor communication. An SMO can provide CRC resources and site-level coordination at selected institutions. This arrangement can be particularly relevant when a study involves many sites or when individual institutions have varying levels of clinical research infrastructure.
The key is to establish clear boundaries. ICH E6(R3) states that transferred trial activities should be appropriately documented and that sponsors should maintain oversight of important activities delegated to service providers.
Without clearly defined responsibilities, the same site issue may be communicated through several channels, while other responsibilities may fall between organizations.
How Does Tigermed Approach Site Management?
Tigermed includes Site Management Organization (SMO) as part of its clinical development service portfolio. Its site management service is focused on providing professional support to investigators and study sites for non-medical judgment activities involved in clinical trials. The company states that its SMO services cover Phase I through Phase IV studies.
Tigermed’s published site-management information identifies full-time clinical research coordinators as a core part of its model. It reports more than 4,000 CRCs, collaboration with more than 1,100 clinical trial sites, coverage across more than 140 cities in China, and more than 4,300 site management projects. These figures are company-reported and should be understood in the context of the stated reporting period and service scope.
Its SMO offering also includes quality management activities such as audits, CAPA coordination, and SOP management. These functions are intended to support site-level quality and consistency rather than replace the responsibilities of investigators, sponsors, or other delegated service providers.
How Should Sponsors Manage the CRO-SMO Interface?
The interface between a CRO and an SMO should be defined before site activities begin. A responsibility matrix can specify who owns site activation, training, monitoring communication, issue escalation, document management, recruitment tracking, and corrective actions.
Communication routes should also be agreed. For example, the SMO may communicate site-level operational issues to the CRO’s project team, while the CRO consolidates information for sponsor reporting. Matters involving medical judgment or investigator responsibilities should remain with the appropriate qualified parties.
ICH E6(R3) emphasizes proportionate oversight of service providers and requires sponsors to assess provider suitability and maintain appropriate oversight of transferred activities.
The objective is not to create additional management layers. Instead, the operating model should make it clear where information originates, who acts on it, and who has authority to make the relevant decision.
What Should Sponsors Check When Selecting an SMO?
Sponsors should evaluate an SMO according to the needs of the study and the characteristics of its participating sites. Relevant considerations may include the availability and training of CRCs, experience in the therapeutic area, geographic coverage, quality systems, communication procedures, and ability to work within the sponsor’s or CRO’s existing processes.
Tigermed describes its CRC workforce as trained in ICH-GCP and GCP requirements and highlights site-level quality management, audit, CAPA, and SOP processes within its SMO model.
For sponsors evaluating a site management organization, the appropriate question is therefore not simply how many sites a provider can support. The more relevant assessment is whether its personnel, processes, and quality controls fit the operational requirements of the specific trial.
How Does SMO Support Fit Into Clinical Research?
SMO support occupies a distinct position within clinical research. Depending on the contracted scope, CROs can provide study-level management and delegated sponsor functions, while SMOs can supply operational resources closer to investigators and individual sites.
When both are involved, clearly documented responsibilities and communication pathways become important. A sponsor may use SMO in clinical research as part of a broader operating model in which site-level coordination complements CRO-led study management.
Ultimately, the distinction between an SMO and a CRO is less about which organization is more important and more about where each operates and which responsibilities it has been assigned. A well-defined interface can help sponsors, CROs, SMOs, investigators, and site staff understand their respective roles while maintaining appropriate oversight of trial quality, participant protection, and data reliability.
